TSC22D3 and experimental autoimmune encephalomyelitis: Subsequent in vivo studies showed that administration of a GILZ peptide inhibits disease development in the experimental autoimmune encephalomyelitis model of multiple sclerosis, in part via effects on T cell activation [81].